Here are the 424B prospectus supplements from Aclaris Therapeutics, Inc. (ACRS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ACRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACRS filings page.
Aclaris Therapeutics, Inc. (ACRS) is offering 7,785,714 shares of common stock and pre-funded warrants to purchase 6,500,000 shares, plus the common shares issuable upon exercise. The offering prices are $3.50 per common share and $3.49999 per warrant; the exercise price is $0.00001 per share. Aclaris estimates net proceeds of approximately $46.7 million and intends to use them for pipeline research and development, working capital and general corporate purposes.
Phase 1b primary analyses of ATI-052 reported a 45% placebo-adjusted mean EASI improvement at day 57 in atopic dermatitis (58% with ATI-052; 13% with placebo); the per-protocol arms included nine treated patients and one placebo patient. In asthma, day-15 mean FeNO reductions were 59% with ATI-052 and 15% with placebo, with a 200 mL placebo-adjusted and absolute mean FEV1 improvement. Aclaris intends to initiate a Phase 2b ATI-052 trial in eosinophilic esophagitis in early 2027.
Cash, cash equivalents and marketable securities were approximately $204.6 million as of September 30, 2026, an unaudited preliminary estimate. The warrants do not expire and are exercisable at any time after issuance; exercise is subject to an initial 9.99% beneficial-ownership cap, which may be increased to no more than 19.99% on at least 61 days’ prior notice. No established trading market exists for the warrants.